Allergy Therapeutics (AGY) has announced its 6-month interim results to end-December 2024, reporting 1H25 group revenues of £34.0m (1H24: £33.6m), in line with the January trading update. Although 1H25 revenue growth of 1% (4% at CER) may appear modest, it marks the second consecutive half-year of growth – an encouraging signal, in our view, that AGY’s prolonged (three-year) period of revenue decline is beginning to stabilise and reverse. While we continue to expect a recovery in revenue, we hav ....
